Abstract:INTRODUCTION: Triple negative breast cancer (TNBC) is an area of high unmet medical need in terms of new effective treatment strategies. Although breast cancer is traditionally considered a 'cold' tumor type, TNBC is the most appropriate subtype for immunotherapeutic strategies; this is due to the high level of tumor infiltrating lymphocytes, PD-L1 expression, and tumor mutational burden compared to other breast cancer subtypes.AREAS COVERED: This review examines the available evidence on the use of immunotherapeutic strategies in early and advanced TNBC, discusses the pitfalls and limitations often encountered in clinical research, and summarizes data on novel promising immunomodulatory approaches that have been explored in early-phase trials.EXPERT OPINION: PD-1-blockade is approved for stage II/III TNBC and for first-line treatment of PD-L1-positive TNBC patients with metastatic disease and should be considered standard of care. However, question marks and difficulties remain; these include the identification of predictive biomarkers to select patients who benefit from the addition of PD1-blockade and the balance between efficacy and long-term toxicity for an individual patient. Numerous treatment combinations and new immunotherapeutic strategies beyond PD1 blockade are being evaluated, thus reflecting a promising evolution towards a more personalized approach, and extended clinical benefit in TNBC.<b>Abbreviations:</b>Triple-negative breast cancer (TNBC); breast cancers (BCs); estrogen receptor (ER); progesterone receptor (PgR); human epidermal growth factor-2 (HER-2); basal-like 1 (BL1), basal-like 2 (BL2); mesenchymal (MES); mesenchymal stem-like (MSL); immunomodulatory (IM); luminal androgen receptor (LAR); basal-like immunosuppressed (BLIS); basal-like immune-activated (BLIA); tumor-infiltrating lymphocytes (TILs); tumor mutational burden (TMB); immune cells (ICs); immunohistochemistry (IHC); overall response rate (ORR); overall survival (OS); progression-free survival (PFS); intention-to-treat (ITT); hazard ratio (HR); confidence interval (CI); Food and Drug Administration (FDA); European Medicines Agency (EMA); immune checkpoint inhibitors (ICI); Combined Positive Score (CPS); disease control rate (DCR); neoadjuvant chemotherapy (NACT); pathological complete response (pCR); event-free survival (EFS); disease-free survival (DFS); residual cancer burden (RCB); San Antonio Breast Cancer Symposium (SABCS); antibody-drug conjugates (ADCs); PARP inhibitors (PARPi); clinical benefit rate (CBR); Histone deacetylase inhibitors (HDACi); Dendritic cell (DC); talimogene laherparepvec (TVEC); granulocyte-macrophage colony-stimulating factor (GM-CSF); mismatch repair deficiency (dMMR).

Therapeutic methods in the treatment of triple-negative breast cancer - a review

Targeting Pivotal Hallmarks of Cancer for Enhanced Therapeutic Strategies in Triple-Negative Breast Cancer Treatment—In Vitro, In Vivo and Clinical Trials Literature Review

A Systematic Review for Targeted Approaches

Recent advances in therapeutic strategies for triple-negative breast cancer

Key Players in the Battle against Triple-Negative Breast Cancer

The treatment landscape of triple-negative breast cancer

Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies

Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy

Triple-Negative Breast Cancer: The Progress of Targeted Therapies and Future Tendencies

Progress in triple negative breast carcinoma pathophysiology: Potential therapeutic targets

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer

Immunotherapeutic Interventions of Triple Negative Breast Cancer

Emerging Therapeutics for Patients with Triple-Negative Breast Cancer

Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies

Progress in Triple Negative Breast Carcinoma Pathophysiology: Potential Therapeutic Targets.

Targeted Treatment of Metastatic Triple‐Negative Breast Cancer: A Systematic Review

Retrospective Observational Study to Determine the Epidemiology and Treatment Patterns of Patients with Triple-Negative Breast Cancer

Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer

Exploring the Potential of Nanomolecular Therapeutic Therapy Options, and Novel Biomarkers in Triple-negative Breast Cancer Treatment

Recent Advances in Immunotherapy for Breast Cancer: A Review

Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer